<DOC>
	<DOC>NCT02856555</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety and tolerability of GS-0976 in adults with nonalcoholic steatohepatitis (NASH).</brief_summary>
	<brief_title>GS-0976 in Adults With Nonalcoholic Steatohepatitis</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Key Meets all of the following conditions: A clinical diagnosis of nonalcoholic fatty liver disease (NAFLD) Screening magnetic resonance imaging proton density fat fraction (MRIPDFF) with ≥ 8% steatosis Screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.5 kPa OR A historical liver biopsy consistent with NASH and noncirrhotic fibrosis Platelet count ≥ 100,000/mm^3 Creatinine Clearance (CLcr ) as calculated by the CockcroftGault equation ≥ 60 ml/min Key Pregnant or lactating females Alanine aminotransferase (ALT) &gt; 5 x upper limit of the normal range (ULN) Other causes of liver disease including autoimmune, viral, and alcoholic liver disease Cirrhosis of the liver Prior history of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding Body mass index (BMI) &lt; 18 kg/m^2 International normalized ratio (INR) &gt; 1.2 unless on anticoagulant therapy Total bilirubin &gt; 1 x ULN, except with diagnosis of Gilbert's syndrome NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>